Q4 2024 Earnings Call Transcript February 13, 2025 Operator: Good morning, and welcome to Agios’ Fourth Quarter 2024 ...

Agios Pharmaceuticals公司日前宣布，“first-in-class”口服丙酮酸激酶（PK）激活剂mitapivat，在3期临床试验ACTIVATE-Kids中达到主要终点。这项研究评估了mitapivat治疗1至18岁PK缺乏症儿童的效果，这些患者不经常接受输血。试验数据显示，mitapivat达到了以血红蛋白应答为指标的主要终点。

Pyruknd won its first approval in 2022 for pyruvate kinase (PK) deficiency, marking the first drug approved to treat the disease. The vaccine was previously approved for use in females who are 9 ...

Despite promising Phase 3 results, safety concerns, namely liver injury, have impacted Agios stock and could affect Pyrukund's approval and market adoption. Read the full report here.

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the twelve research firms that are currently covering the stock, ...

If there were a do-it-all nutrient award, it might go to magnesium. The humble mineral plays a critical role in helping your body function successfully. “Aside from being a component of our ...